000			04308nam a22004215i 4500
001			289245
003			MX-SnUAN
005			20160429154702.0
007			cr nn 008mamaa
008			150903s2008 xxu| o |||| 0|eng d
020			_a9781597454704 _99781597454704
024	7		_a10.1007/9781597454704 _2doi
035			_avtls000343119
039		9	_a201509030902 _bVLOAD _c201405050252 _dVLOAD _y201402061148 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC254-282
100	1		_aBronchud, Miguel H. _eeditor. _9319381
245	1	0	_aPrinciples of Molecular Oncology / _cedited by Miguel H. Bronchud, Mary Ann Foote, Giuseppe Giaccone, Olufunmilayo Olopade, Paul Workman.
250			_aThird Edition.
264		1	_aTotowa, NJ : _bHumana Press, _c2008.
300			_brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
500			_aSpringer eBooks
505	0		_aSelecting the Right Targets for Cancer Therapy -- Clinical Importance of Prognostic Factors -- Genetic Markers in Sporadic Tumors -- Genetic Markers in Breast Tumors with Hereditary Predisposition -- Circulating Tumor Markers -- Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways -- Gene Expression Arrays for Pathway Analysis in Cancer Research -- Signaling Pathways in Cancer -- Estrogen Receptor Pathways and Breast Cancer -- Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics -- Angiogenesis Switch Pathways -- Apoptosis Pathways and New Anticancer Agents -- Genomic Instability, DNA Repair Pathways and Cancer -- Epigenomics and Cancer -- Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well? -- Aurora Kinases: A New Target for Anticancer Drug Development -- Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways -- Suicide Gene Therapy -- Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs -- A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?.
520			_aDrawing on years of significant scientific advances and clinical developments, the editors of POMO III have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, pharmacogenomics, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules. The first edition of this book (Humana Press, 2000) was also the first comprehensive presentation of the concept of cancer as a "disease process" involving key regulatory pathways. The second edition (2004) reaffirmed this dynamic concept, incorporating more recent evidence, and introducing such new topics of special interest as the combination of molecular diagnostics-expression profiling of genes and proteins- with developmental therapeutics, and the "binary state" concept (active/inactive) that seeks more relevant targets within the global molecular matrix of a given cancer. Comprehensive and intellectually stimulating, POMO III not only clearly elucidates the fundamentals of this dramatically advancing field, but also interprets the vast and often complex molecular data available. It fills a much neglected gap between "information" and "knowledge," and holds out the hope of new anticancer strategies that will reduce the process of carcinogenesis, cancer cell proliferation and significantly reduce metastasis.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aFoote, Mary Ann. _eeditor. _9319382
700	1		_aGiaccone, Giuseppe. _eeditor. _9319383
700	1		_aOlopade, Olufunmilayo. _eeditor. _9319384
700	1		_aWorkman, Paul. _eeditor. _9319385
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781934115251
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-59745-470-4 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c289245 _d289245